The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial

Induction chemotherapy with docetaxel, cisplatin and 5

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Neoadjuvant cisplatin and fluorouracil versus epirubicin

Progress in systemic therapy for advanced-stage urothelial

Avelumab as neoadjuvant therapy in patients with urothelial non